Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CBT Starts Phase Ib Trial of PD-1 Candidate in Australia

publication date: Jul 27, 2018

CBT Pharma, a US-China company, announced plans to begin an Australian Phase Ib trial of its PD-1 candidate. CBT was founded by CRO CrownBio (TW: 6554), which has supplied CBT with three immuno-oncology candidates, including the PD-1 molecule, known as CBT-501. CBT's China partner, Genor Biopharma, is responsible for conducting the Australian trials. It plans to test CBT-501 in four separate types of advanced or relapsed/recurrent solid tumors, with each arm enrolling 20 patients. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital